Pupm&Dump trading strategy idea.
$ATHX is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $1,76;
stop-loss — $1,87;
take-profit — $1,56.
Do not view this idea as a recommendation for trading or investing. It is...
Gap up, trendline break
Possible double bottom
WR Crossed -80
OBV>OBV34
Entry 1.5
Stop 1.3
Target 3.0
Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader. I trade option to test my trading plan with small cost.
I created some tradingview scripts to improve my...
Athersys Inc is a clinical-stage biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is a significant unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological...
Athersys, Inc.
The solid gain came after the company and the University of Texas Health Science Center at Houston announced the enrollment of the first patient in a phase 2 clinical study evaluating the company's MultiStem cell therapy as a potential early treatment for traumatic injuries.
The company doesn't have any approved products on the market ye t, so...
So this might be trash, but I think breaking above $2.54 may signal real positive movement. The MACD is tapping 0.10, while the Ichimoku has the lagging indicator breaking out for more than a day. Add all that together with triple the average volume today (Feb. 2nd), a couple larger than average buys, and investor meetings coming soon (Feb 16th) and you have it...
ATHX recently broke out of a descending wedge that took it from the top of the channel to the bottom...after 9 weeks of consolidation, it is now trading above all major moving averages...monday saw a break above the 200 day ma and today saw a retest...macd is in positive territory and looks to be holding...target for descending wedge coincides nicely with the top...
ATHX has a near doom death cross approaching as the 50 DEMA is coming close to the 200 DEMA. Overall, outside chance here for a WXYXZ correction to be taking place, but where Z finishes remains unknown.
RSI is low to nearing oversold.
Will try to provide update next week.
Do not take as financial advice.
This one, though seemingly violent at times, has followed a complete and natural ABC Correction (as well as a proper ABC within each of these legs as well, broken down above) after a big first leg up. Expectations for a strong 3rd wave - C Wave up (abCde) are growing by the day. As you can see, the resistance that has been hit multiple times since April has...
Was working today on my list and found this awesome looking chart in my watch list. Been waiting for this for some time now, will look to buy into within the next few days. I think its safe to buy immediately but I need to free up some cash first :). Hope some of my followers will make some money on this tip and will share their victory here, thanks in advance.
Here is an update to yesterday, a quick, sharp ABC recovery has taken place. Time will tell if this results in this being just the first of a more complex ABC or if this restocked the stochastic enough to propel it onward.
Purely for my own use as I've been following this (as well as a few other stocks since COVID surged this market sector) for a couple months now.
I see 3 options ahead of us after the immediate rejection today near 3.30 mark.
1) A quick correction before another rise after another bounce off the support
2) A two week correction before a bounce off support to...
NASDAQ:ATHX Started going in a down trend with a double top forming, checking to see if it passes through it's resistance band to place the short order. Let me know how it looks, im 18 and still learning.
Contextual immersion trading strategy idea.
Athersys is a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and...
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
NASDAQ
